Drugs / LM-168
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06868199 | May 2025 → Aug 2027 expected | cancer | LaNova Medicines Limited | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07669415 | Jun 2026 → Dec 2027 expected | neoplasm | LaNova Medicines Limited | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM-168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07669415 ↗ |
| Route | Intravenous | “Q3W,Intravenous Drip” NCT06868199 ↗ |